Biocon to ramp up investments in small molecules businessIllustrative image – not actual.
Biocon is planning to ramp up investment in its small and complex drug molecules vertical over coming years.

For this augmentation proceeds will be utilised from a proposed initial public offering of its biologics operations.

The company plans to invest a part of the funds it collects from private equity (PE) firms and the IPO of subsidiary Biocon Biologics India back into the small molecules operations.

← All latest storiesBack to top →